Other
Main Filters
Other
| Acera Surgical Inc | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| RMESH-1.5X2 | 0 | - | ||
| RMESH-2X2 | 0 | - | ||
| RMESH-3X3 | 0 | - | ||
| RMESH-4X5 | 0 | - | ||
| RMESH-5X7 | 0 | - | ||
| RMINI-100 | 0 | - | ||
| RMINI-1000 | 0 | - | ||
| RMINI-2000 | 0 | - | ||
| RMINI-250 | 0 | - | ||
| RMINI-500 | 0 | - | ||
| RWM1-0.5X1 | 0 | - | ||
| RWM1-1.5X2 | 0 | - | ||
| RWM1-5X7 | 0 | - | ||
| CTK BIOTECH INC. | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| R0182CHT | 0 | - | ||
| R0182CHT | 0 | - | ||
| R0182CHT | 0 | - | ||
| HYDROFERA, LLC | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| HBRS3535 | 0 | - | ||
| LUMIQUICK DIAGNOSTICS, INC. | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 1N40C5-1-US-BS | 0 | - | ||
| Neuropace, Inc. | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 5107 | 0 | - | ||
| EX-01-K | 0 | - | ||
| SAFE N' SIMPLE LLC | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| SNS52244 | 0 | - | ||
| Sense Technology, Inc. | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| G3 | 0 | - | ||
| Simple Science LLC | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 7-5588-04 | 0 | - | ||
| 7-7178-04 | 0 | - | ||
| 7-7208-03 | 0 | - | ||
| 7-7260-03 | 0 | - | ||
| 7-7307-01 | 0 | - | ||
| 7-7314-02 | 0 | - | ||
| 7-7338-01 | 0 | - | ||
| 7-7352-03 | 0 | - | ||
| 7-7376-02 | 0 | - | ||
| 7-7390-03 | 0 | - | ||
| 7-7635-00 | 0 | - | ||
| Urotronic, Inc. | ||||
| CATALOG # | QTY | PRICE | DESCRIPTION | |
| 1110-06030B | 0 | - | ||
| 1110-06050B | 0 | - | ||
| 1110-08030B | 0 | - | ||
| 1110-08050B | 0 | - | ||
| 1110-10030B | 0 | - | ||
| 1110-10050B | 0 | - | ||
| 1110-12030B | 0 | - | ||
| 1110-12050B | 0 | - | ||
| 1113-30030 | 0 | - | ||
| 1113-30040 | 0 | - | ||
| 1113-30045 | 0 | - | ||
| 1137-30030 | 0 | - | ||
| 1137-30035 | 0 | - | ||
| 1189-30030 | 0 | - | ||
| 1189-30035 | 0 | - | ||
| 1189-30040 | 0 | - | ||
| 1189-30045 | 0 | - | ||
83,930 Results
Results Per Page
- 50
- 100
- 250
Catalog #
AvailableQty
Starting At
Name
Company Name
Description
0
-
Rapid SARS-CoV-2 Antigen Test Card
LUMIQUICK DIAGNOSTICS, INC.
The Rapid SARS-CoV-2 Antigen Test Card is a single use rapid lateral flow chromatographic immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 and older, when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests. The test is authorized for individuals with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other epidemiological reasons to suspect COVID-19.This test is also authorized for non-prescription home use with adult-collected anterior nasal (nares) swab samples from individuals aged 2 years and older when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests. The test is authorized for individuals aged 2 years and older with symptoms of COVID-19 within the first 6 days of symptom onset, or individuals without symptoms or other epidemiological reasons to suspect COVID-19.
0
-
NeuroPace® Remote Monitor Kit
Neuropace, Inc.
The NeuroPace® Remote Monitor package contains 1 NeuroPace® Remote Monitor, and 1 Carrying Case.
0
-
Explant Kit
Neuropace, Inc.
The Explant Kit package contains 2 Lead Caps and 1 Torque Driver.
0
-
ImmuView COVID-19 Antigen Home Test
CTK BIOTECH INC.
The lmmuView® COVID-19 Antigen Home Test is a lateral flow immunoassay device intended for the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older or adult collected anterior nasal (nares) swab samples from individuals aged two years or older. This test is authorized for individuals with symptoms of COVID-19 within the first 7 days of symptom onset when tested at least twice over three days with at least 48 hours between tests, and for individuals without symptoms or other epidemiological reasons to suspect COVID-19, when tested at least three times over five days with at least 48 hours between tests.The lmmuView® COVID-19 Antigen Home Test does not differentiate between SARS-CoV and SARS-CoV-2.Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen, which is generally detectable in anterior nasal (nares) swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Individuals who test positive with the lmmuView® COVID-19 Antigen Home Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary.All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks. Negative results should be
0
-
ImmuView COVID-19 Antigen Home Test
CTK BIOTECH INC.
The lmmuView® COVID-19 Antigen Home Test is a lateral flow immunoassay device intended for the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older or adult collected anterior nasal (nares) swab samples from individuals aged two years or older. This test is authorized for individuals with symptoms of COVID-19 within the first 7 days of symptom onset when tested at least twice over three days with at least 48 hours between tests, and for individuals without symptoms or other epidemiological reasons to suspect COVID-19, when tested at least three times over five days with at least 48 hours between tests.The lmmuView® COVID-19 Antigen Home Test does not differentiate between SARS-CoV and SARS-CoV-2.Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen, which is generally detectable in anterior nasal (nares) swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Individuals who test positive with the lmmuView® COVID-19 Antigen Home Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary.All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks. Negative results should be
0
-
ImmuView COVID-19 Antigen Home Test
CTK BIOTECH INC.
The lmmuView® COVID-19 Antigen Home Test is a lateral flow immunoassay device intended for the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older or adult collected anterior nasal (nares) swab samples from individuals aged two years or older. This test is authorized for individuals with symptoms of COVID-19 within the first 7 days of symptom onset when tested at least twice over three days with at least 48 hours between tests, and for individuals without symptoms or other epidemiological reasons to suspect COVID-19, when tested at least three times over five days with at least 48 hours between tests.The lmmuView® COVID-19 Antigen Home Test does not differentiate between SARS-CoV and SARS-CoV-2.Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen, which is generally detectable in anterior nasal (nares) swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Individuals who test positive with the lmmuView® COVID-19 Antigen Home Test should self-isolate and seek follow-up care with their physician or healthcare provider as additional testing may be necessary.All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks. Negative results should be
0
-
PulStar
Sense Technology, Inc.
The PulStar Spine Mobilization Device is intended for use by chiropractors, physical therapists and physicians for mobilization of the spine. The device consists of a hand-held impulse head attached to an electronic control module. The control module is connected to an Apple computer through a USB cable. Appropriate software is used to display the results of tissue compliance measurements.Intended Use and operation: Intended use of the PulStar is for the treatment of musculoskeletal pain due to joint subluxation, restricted joint mobility, myofacial spasm and ligamentous strain. The clinician uses a hand held impulse head to test the stiffness of the patient’s spine at each vertebral level, the results of this procedure are recorded in the patient file in a computer database and displayed on the computer screen. The clinician then decides where therapy is needed and applies multiple impulses with the impulse head to those areas of the body of the patient with the intent of reducing spinal stiffness. After treatment, the clinician repeats the initial test of the patient’s spine to document changes in stiffness effected by the therapy.
0
-
SkinSmart Antimicrobial Wound and Skin Cleanser for Wound Therapy
Simple Science LLC
SkinSmart Antimicrobial Wound and Skin Cleanser for Wound Therapy 2oz
0
-
SkinSmart Antimicrobial Piercing and Tattoo Aftercare
Simple Science LLC
SkinSmart Antimicrobial Piercing and Tattoo Aftercare 8oz
0
-
SkinSmart Antimicrobial Men's Intimate Care
Simple Science LLC
SkinSmart Antimicrobial Men's Intimate Care 8oz
0
-
SkinSmart Antimicrobial Rash and Hive Care
Simple Science LLC
SkinSmart Antimicrobial Rash and Hive Care 8oz
0
-
SkinSmart Antimicrobial Perineal Cleanser
Simple Science LLC
SkinSmart Antimicrobial Perineal Cleanser 8oz
0
-
SkinSmart Antimicrobial Face Cleanser (Virus)
Simple Science LLC
SkinSmart Antimicrobial Face Cleanser (Virus) 2oz
0
-
SkinSmart Antimicrobial Skin Cleanser (Baby Eczema)
Simple Science LLC
SkinSmart Antimicrobial Skin Cleanser (Baby Eczema)
0
-
SkinSmart Antimicrobial Skin Cleanser (Nipple Spray)
Simple Science LLC
SkinSmart Antimicrobial Skin Cleanser (Nipple Spray) 8oz
0
-
SkinSmart Antimicrobial Face Cleanser (Acne)
Simple Science LLC
SkinSmart Antimicrobial Face Cleanser (Acne) 8oz
0
-
SkinSmart Antimicrobial Foot Cleanser
Simple Science LLC
SkinSmart Antimicrobial Foot Cleanser 8oz
0
-
SkinSmart Antimicrobial Skin Cleanser for Eczema Therapy
Simple Science LLC
SkinSmart Antimicrobial Skin Cleanser for Eczema Therapy 2oz
0
-
Restrata Meshed
Acera Surgical Inc
The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds.
0
-
Restrata Meshed
Acera Surgical Inc
The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds.
0
-
Restrata Meshed
Acera Surgical Inc
The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds.
0
-
Restrata Meshed
Acera Surgical Inc
The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds.
0
-
Restrata Meshed
Acera Surgical Inc
The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds.
0
-
Restrata Wound Matrix
Acera Surgical Inc
The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds.
0
-
Restrata Wound Matrix
Acera Surgical Inc
The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds.
0
-
Restrata Wound Matrix
Acera Surgical Inc
The Restrata Wound Matrix is a sterile, single use device intended for use in local management of wounds.
0
-
Optilume BPH Catheter System
Urotronic, Inc.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
0
-
Optilume BPH Catheter System
Urotronic, Inc.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
0
-
Optilume BPH Drug Coated Balloon Catheter
Urotronic, Inc.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
0
-
Optilume BPH Pre-dilation Catheter
Urotronic, Inc.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
0
-
Optilume BPH Drug Coated Balloon Catheter
Urotronic, Inc.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
0
-
Optilume Urethral Drug Coated Balloon
Urotronic, Inc.
The Optilume® Urethral Drug Coated Balloon (Optilume DCB) Catheter is a 0.038” (0.97 mm) over-the-wire (OTW) guidewire compatible catheter with a dual lumen design and a tapered, atraumatic tip. The Optilume DCB is used to exert radial force to dilate narrow urethral segments (strictures). The distal end of the catheter has a semi-compliant inflatable balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel. The drug coating covers the working length of the balloon body. The device has two radiopaque marker bands that indicate the working length of the balloon where the drug coating is applied. The drug coated balloon is covered with a protective sheath that is discarded prior to use.
0
-
Optilume Urethral Drug Coated Balloon
Urotronic, Inc.
The Optilume® Urethral Drug Coated Balloon (Optilume DCB) Catheter is a 0.038” (0.97 mm) over-the-wire (OTW) guidewire compatible catheter with a dual lumen design and a tapered, atraumatic tip. The Optilume DCB is used to exert radial force to dilate narrow urethral segments (strictures). The distal end of the catheter has a semi-compliant inflatable balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel. The drug coating covers the working length of the balloon body. The device has two radiopaque marker bands that indicate the working length of the balloon where the drug coating is applied. The drug coated balloon is covered with a protective sheath that is discarded prior to use.
0
-
Optilume Urethral Drug Coated Balloon
Urotronic, Inc.
The Optilume® Urethral Drug Coated Balloon (Optilume DCB) Catheter is a 0.038” (0.97 mm) over-the-wire (OTW) guidewire compatible catheter with a dual lumen design and a tapered, atraumatic tip. The Optilume DCB is used to exert radial force to dilate narrow urethral segments (strictures). The distal end of the catheter has a semi-compliant inflatable balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel. The drug coating covers the working length of the balloon body. The device has two radiopaque marker bands that indicate the working length of the balloon where the drug coating is applied. The drug coated balloon is covered with a protective sheath that is discarded prior to use.
0
-
Optilume Urethral Drug Coated Balloon
Urotronic, Inc.
The Optilume® Urethral Drug Coated Balloon (Optilume DCB) Catheter is a 0.038” (0.97 mm) over-the-wire (OTW) guidewire compatible catheter with a dual lumen design and a tapered, atraumatic tip. The Optilume DCB is used to exert radial force to dilate narrow urethral segments (strictures). The distal end of the catheter has a semi-compliant inflatable balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel. The drug coating covers the working length of the balloon body. The device has two radiopaque marker bands that indicate the working length of the balloon where the drug coating is applied. The drug coated balloon is covered with a protective sheath that is discarded prior to use.
0
-
Optilume Urethral Drug Coated Balloon
Urotronic, Inc.
The Optilume® Urethral Drug Coated Balloon (Optilume DCB) Catheter is a 0.038” (0.97 mm) over-the-wire (OTW) guidewire compatible catheter with a dual lumen design and a tapered, atraumatic tip. The Optilume DCB is used to exert radial force to dilate narrow urethral segments (strictures). The distal end of the catheter has a semi-compliant inflatable balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel. The drug coating covers the working length of the balloon body. The device has two radiopaque marker bands that indicate the working length of the balloon where the drug coating is applied. The drug coated balloon is covered with a protective sheath that is discarded prior to use.
0
-
Optilume Urethral Drug Coated Balloon
Urotronic, Inc.
The Optilume® Urethral Drug Coated Balloon (Optilume DCB) Catheter is a 0.038” (0.97 mm) over-the-wire (OTW) guidewire compatible catheter with a dual lumen design and a tapered, atraumatic tip. The Optilume DCB is used to exert radial force to dilate narrow urethral segments (strictures). The distal end of the catheter has a semi-compliant inflatable balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel. The drug coating covers the working length of the balloon body. The device has two radiopaque marker bands that indicate the working length of the balloon where the drug coating is applied. The drug coated balloon is covered with a protective sheath that is discarded prior to use.
0
-
Optilume Urethral Drug Coated Balloon
Urotronic, Inc.
The Optilume® Urethral Drug Coated Balloon (Optilume DCB) Catheter is a 0.038” (0.97 mm) over-the-wire (OTW) guidewire compatible catheter with a dual lumen design and a tapered, atraumatic tip. The Optilume DCB is used to exert radial force to dilate narrow urethral segments (strictures). The distal end of the catheter has a semi-compliant inflatable balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel. The drug coating covers the working length of the balloon body. The device has two radiopaque marker bands that indicate the working length of the balloon where the drug coating is applied. The drug coated balloon is covered with a protective sheath that is discarded prior to use.
0
-
Optilume Urethral Drug Coated Balloon
Urotronic, Inc.
The Optilume® Urethral Drug Coated Balloon (Optilume DCB) Catheter is a 0.038” (0.97 mm) over-the-wire (OTW) guidewire compatible catheter with a dual lumen design and a tapered, atraumatic tip. The Optilume DCB is used to exert radial force to dilate narrow urethral segments (strictures). The distal end of the catheter has a semi-compliant inflatable balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel. The drug coating covers the working length of the balloon body. The device has two radiopaque marker bands that indicate the working length of the balloon where the drug coating is applied. The drug coated balloon is covered with a protective sheath that is discarded prior to use.
0
-
Optilume BPH Catheter System
Urotronic, Inc.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
0
-
Optilume BPH Catheter System
Urotronic, Inc.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
0
-
Optilume BPH Drug Coated Balloon Catheter
Urotronic, Inc.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
0
-
Optilume BPH Pre-dilation Catheter
Urotronic, Inc.
The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
